Monte Rosa Therapeutics, Inc. (GLUE) Return on equity 2023–2025
Monte Rosa Therapeutics, Inc. (GLUE) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-31.2%FY2025 · since FY2023: -60.5% → -31.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -31.2% | +29.5 pp |
| FY2024 | -60.7% | -0.2 pp |
| FY2023 | -60.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice